Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Caralluma Fimbriata Extract on Stress, Sleep and Neurotransmitters
NCT05232266Phase 3Completed
- Sponsor
- RDC Clinical
- Start
- Feb 2022
- Primary completion
- May 2023
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial (2 arms), sponsored by RDC Clinical. Primary endpoints: Perceived Stress Scale at Week 8 and Salivary Cortisol levels at Week 8. Started Feb 2022; status: completed.
Beyond the preview
Go deeper on NCT05232266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05232266.